Application of remazolam besylate for injection in painless gastroscopy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049683

Enrollment

Unknown

Registered

2021-08-08

Start date

2021-08-16

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscope

Interventions

Control group:propofol

Experimental group 1:remazolam besylate + propofol

Experimental group 2:remazolam besylate

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years; 2. 18kg/m^2 <BMI<30kg/m^2; 3. American Society of Anesthesiologists (ASA) grades I to II; 4. Voluntarily participate and sign the informed consent; 5. There are no contraindications for painless gastroscopy.

Exclusion criteria

Exclusion criteria: 1. Patients with acute respiratory infection; 2. Patients with obstructive sleep apnea syndrome; 3. Patients who are allergic to related anesthetics; 4. Patients who take analgesic and sedative drugs for a long time; 5. Patients with acute upper gastrointestinal bleeding; 6. Patients who are pregnant or breastfeeding; 7. Patients with mental illness.

Design outcomes

Primary

Measure	Time frame
Blood pressure;	—

Secondary

Measure	Time frame
Wake up time after examination;Disappearance time of eyelash reflex;Gastroscopy time;Nausea and vomiting;Hypotension;Bradycardia;Hypoxemia;	—

Countries

China

Contacts

Public ContactDong Shuhua

Nuclear Industry 416 Hospital

382217690@qq.com+86 13880892273

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026